文献速递生殖医学

来曲唑卵巢刺激周期中黄体期孕酮支持不提高妊娠率

Luteal phase support with progesterone does not improve pregnancy rates in patients undergoing ovarian stimulation with letrozole.
PubMed 文献 · Reprod Biomed Online · 2022-09-20

回顾性队列研究纳入2018年1月至2021年10月来曲唑卵巢刺激联合宫腔内人工授精或定时性交的492个周期。阴道孕酮黄体支持组临床妊娠率为11.6%(45/387),未支持组为13.3%(14/105),P=0.645;多因素校正后OR为1.15(95%CI 0.48-2.75,P=0.762),活产率两组分别为10.7%(41/384)和12.5%(13/104)。结论认为阴道孕酮黄体支持未显著改善临床妊娠率。

要点

  • 来曲唑刺激周期中阴道孕酮黄体支持组临床妊娠率11.6%,未支持组13.3%,无显著差异。
  • 校正年龄、BMI、排卵障碍诊断和多卵泡发育后,OR 1.15(95%CI 0.48-2.75),未达统计学显著。
  • 活产率孕酮组10.7% vs 未用组12.5%,P=0.599,无显著差异。

核心结论

  • 来曲唑卵巢刺激周期中使用阴道孕酮进行黄体支持未显著提高临床妊娠率。

研究设计与样本

  • 回顾性队列研究,纳入2018年1月至2021年10月接受来曲唑卵巢刺激联合宫腔内人工授精或定时性交的患者。
  • 共纳入273例患者的492个来曲唑卵巢刺激周期,其中387个周期(78.7%)使用阴道孕酮黄体支持,105个周期(21.3%)未使用。
  • 主要结局为每周期临床妊娠率,采用单因素及多因素逻辑回归分析校正年龄、体质指数、抗苗勒管激素浓度、排卵障碍诊断和多卵泡发育等协变量。
  • 次要结局包括自然流产、生化妊娠和异位妊娠,并在二次分析中计算活产率。

主要发现

  • 未校正临床妊娠率:孕酮组11.6%(45/387) vs 未用组13.3%(14/105),P=0.645。
  • 校正年龄、BMI、排卵障碍诊断和多卵泡发育后,孕酮组临床妊娠的OR为1.15(95%CI 0.48-2.75,P=0.762),未达统计学显著。
  • 活产率:孕酮组10.7%(41/384) vs 未用组12.5%(13/104),P=0.599。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does luteal phase support with vaginal progesterone improve clinical pregnancy rates in patients undergoing ovarian stimulation with letrozole? DESIGN: This was a retrospective cohort study of patients undergoing ovarian stimulation with letrozole paired with intrauterine insemination (IUI) or timed intercourse (TIC) from January 2018 to October 2021. The primary outcome of clinical pregnancy rate (CPR) was calculated for cycles with and without luteal phase progesterone support. Univariate logistic regressions were done to evaluate predictor variables for CPR. Clinically important covariates including age, body mass index, anti-Müllerian hormone concentration, diagnosis of ovulatory dysfunction and multifollicular development were included in a multivariate analysis evaluating the relationship between luteal progesterone use and odds of clinical pregnancy. Secondary outcomes including spontaneous abortion, biochemical pregnancy and ectopic pregnancy were calculated. Live birth rates were calculated for cycles in a secondary analysis. RESULTS: A total of 492 letrozole ovarian stimulation cycles in 273 patients were included. Of these cycles, 387 (78.7%) used vaginal progesterone for luteal support and 105 (21.3%) did not. The unadjusted CPR per cycle was 11.6% (45/387) with progesterone and 13.3% (14/105) without progesterone (P = 0.645). After adjusting for significant covariates including age, BMI, diagnosis of ovulatory dysfunction and multifollicular development, the odds for clinical pregnancy were not significantly improved in cycles with exogenous progesterone (odds ratio [OR] 1.15, 95% confidence interval [CI] 0.48-2.75, P = 0.762). A follow-up analysis demonstrated that live birth rate was 10.7% (41/384) with and 12.5% (13/104) without luteal progesterone, respectively (P = 0.599). CONCLUSIONS: Luteal support with vaginal progesterone does not significantly improve CPR in ovarian stimulation cycles using letrozole.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Dilday E, Gigg M, Hoyos L, et al. Luteal phase support with progesterone does not improve pregnancy rates in patients undergoing ovarian stimulation with letrozole. Reprod Biomed Online. 2022. PMID: 36396533. doi:10.1016/j.rbmo.2022.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。